10 recruiting, 8 completed, 5 active not recruiting, 3 unknown. 10 Phase 3, 9 Phase 2, 2 Early Phase 1, 2 Phase 1, 1 Not applicable.
Follow Myasthenia Gravis, Generalized: new trials by email Literature Review of Myasthenia Gravis, Generalized trials Research Report on Myasthenia Gravis, Generalized
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360 MyoSense 360 - Myasthenia Gravis, Generalized | Not applicable | Recruiting | Ad scientiam | 100 | 2026-10-06 | 2026-11-05 |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Recruiting | Dianthus Therapeutics | 195 | 2026-06-29 | 2026-10-30 |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Povetacicept, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 34 | 2026-05-13 | 2026-10-29 |
| Study of Aritinercept in Patients With Generalized Myasthenia Gravis Aritinercept, Placebo - Myasthenia Gravis, Generalized | Phase 1 / Phase 2 | Recruiting | Aurinia Pharmaceuticals Inc. | 81 | 2026-04-22 | 2026-08-03 |
| AXIS MG Patient Registry Myasthenia Gravis (MG), Myasthenia Gravis, Generalized | Recruiting | Autoimmune Neurology Alliance | 1000 | 2026-03-19 | 2026-08-17 | |
| Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis Myasthenia Gravis, Myasthenia Gravis, Generalized | Not yet recruiting | BioSensics | 50 | 2026-01-01 | 2025-11-04 | |
| Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod Efgartigimod - Myasthenia Gravis, Generalized | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Nice | 50 | 2025-09-19 | 2026-09-03 |
| Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis Ravulizumab - Myasthenia Gravis, Generalized | Recruiting | AstraZeneca | 50 | 2025-05-15 | 2026-09-16 | |
| The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis Dose level 1 group, Dose level 2 group, Dose level 3 group - Myasthenia Gravis, Generalized | Phase 1 | Active not recruiting | Ting Chang, MD | 10 | 2025-05-01 | 2026-05-27 |
| Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T - Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized | Early Phase 1 | Not yet recruiting | Xuanwu Hospital, Beijing | 25 | 2025-02-28 | 2025-01-01 |
| Markers of Favorable Response to Complement Inhibitors Therapy Myasthenia Gravis, Generalized | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 50 | 2024-06-05 | 2025-08-01 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Efgartigimod IV, Placebo IV - Generalized Myasthenia Gravis, gMG | Phase 3 | Active not recruiting | argenx | 119 | 2024-04-16 | 2026-08-10 |
| A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Dianthus Therapeutics | 65 | 2024-02-23 | 2026-07-27 |
| Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research Post-Acute COVID-19 Syndrome, ME/CFS | Recruiting | Brain Inflammation Collaborative | 10000 | 2023-07-05 | 2026-01-22 | |
| Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Tocilizumab Injection - Myasthenia Gravis, Generalized | Phase 2 / Phase 3 | Unknown | Tang-Du Hospital | 64 | 2023-04-01 | 2024-01-22 |
| Study of Telitacicept in Generalized Myasthenia Gravis Telitacicept, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Completed | RemeGen Co., Ltd. | 114 | 2023-03-28 | 2025-05-23 |
| Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis Tocilizumab Injectable Product - Myasthenia Gravis, Generalized | Phase 2 | Recruiting | Tang-Du Hospital | 64 | 2022-07-21 | 2025-05-01 |
| Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Rituximab, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 40 | 2022-02-28 | 2025-08-01 |
| Predictors and Prognostic Factors of Myasthenia Gravis Outcome Drug treatment of myasthenia gravis and treatment of crisis - Myasthenia Gravis, Autoimmune Diseases of the Nervous System | Unknown | Assiut University | 30 | 2022-01-01 | 2024-07-31 | |
| Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Tofacitinib 5 MG - Myasthenia Gravis, Generalized | Early Phase 1 | Completed | Huashan Hospital | 19 | 2020-06-11 | 2025-09-16 |
Showing 20 of 30. Sign in to see all of them.
Myasthenia Gravis (30) · Autoimmune Diseases of the Nervous System (3) · Autoimmune Diseases (2) · Multiple Sclerosis (2) · Neuromuscular Junction Diseases (2) · Anorexia Nervosa (1) · Anxiety Disorders (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Autonomic Nervous System Diseases (1) · Avoidant Restrictive Food Intake Disorder (1) · Brain Injuries, Traumatic (1) · Bulimia Nervosa (1) · Celiac Disease (1) · Colitis, Ulcerative (1)
Immune System Diseases (30) · Neoplasms (30) · Neoplasms by Site (30) · Nervous System Neoplasms (30) · Neurodegenerative Diseases (30) · Neuromuscular Diseases (30) · Paraneoplastic Syndromes (30) · Paraneoplastic Syndromes, Nervous System (30) · Nervous System Diseases (29) · Autoimmune Diseases (28) · Neuromuscular Junction Diseases (28) · Autoimmune Diseases of the Nervous System (27) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3)
Amifampridine (1) · Mycophenolic Acid (1) · Rituximab (1) · eculizumab (1) · efgartigimod alfa (1) · iscalimab (1) · ravulizumab (1) · telitacicept (1) · tocilizumab (1) · tofacitinib (1) · zilucoplan (1)
Dianthus Therapeutics (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Tang-Du Hospital (2) · Ad scientiam (1) · Alexion Pharmaceuticals, Inc. (1) · Assiut University (1) · AstraZeneca (1) · Aurinia Pharmaceuticals Inc. (1) · Autoimmune Neurology Alliance (1) · BioSensics (1) · Brain Inflammation Collaborative (1) · Cartesian Therapeutics (1) · Catalyst Pharmaceuticals, Inc. (1) · Centre Hospitalier Universitaire de Nice (1) · CuraVac (1)
United States (16) · Canada (7) · China (7) · France (7) · Germany (6) · Italy (6) · Poland (6) · Denmark (4) · Spain (4) · United Kingdom (4) · Belgium (3) · Czechia (3) · Netherlands (3) · Norway (3) · Georgia (2)
Raffaele Iorio (2) · Gary R Cutter, PhD (1) · Jared R Adams, MD, PhD (1) · Megan L Fitzgerald, PhD (1) · Neelam Goyal, MD (1) · Renato Mantegazza, MD (1) · Richard J Nowak, MD, MS (1) · Rudy Mercelis, MD, PhD (1) · Sabine Hazan (1) · Srikanth Muppidi, MD (1) · Ting Chang (1) · Ting Chang, MD,PHD (1)
PMID 25032816, PMID 35350948, PMID 35816681, PMID 37059508, PMID 37353270, PMID 37353278, PMID 38400914, PMID 39314260, PMID 40450840, PMID 40504283, PMID 41514038, PMID 41514039
2016 (1), 2017 (1), 2025 (1), R44NS122672 (1)